Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis

Open access

Abstract

Aims: Angiopoietin-like protein 3 (ANGPTL3) and 4 (ANGPTL4) inhibit lipoprotein lipase (LPL) and represent emerging drug targets to lower circulating triglycerides and reduce cardiovascular risk. To investigate the molecular effects of genetic mimicry of ANGPTL3 and ANGPTL4 inhibition and compare them to the effects of genetic mimicry of LPL enhancement. Methods and results: Associations of genetic variants in ANGPTL3 (rs11207977-T), ANGPTL4 (rs116843064-A), and LPL (rs115849089-A) with an extensive serum lipid and metabolite profile (208 measures) were characterized in six cohorts of up to 61 240 participants. Genetic associations with anthropometric measures, glucose-insulin metabolism, blood pressure, markers of kidney function, and cardiometabolic endpoints via genome-wide summary data were also explored. ANGPTL4 rs116843064-A and LPL rs115849089-A displayed a strikingly similar pattern of associations across the lipoprotein and lipid measures. However, the corresponding associations with ANGPTL3 rs11207977-T differed, including those for low-density lipoprotein and high-density lipoprotein particle concentrations and compositions. All three genotypes associated with lower concentrations of an inflammatory biomarker glycoprotein acetyls and genetic mimicry of ANGPTL3 inhibition and LPL enhancement were also associated with lower C-reactive protein. Genetic mimicry of ANGPTL4 inhibition and LPL enhancement were associated with a lower waist-to-hip ratio, improved insulin-glucose metabolism, and lower risk of coronary heart disease and type 2 diabetes, whilst genetic mimicry of ANGPTL3 was associated with improved kidney function. Conclusions: Genetic mimicry of ANGPTL4 inhibition and LPL enhancement have very similar systemic metabolic effects, whereas genetic mimicry of ANGPTL3 inhibition showed differing metabolic effects, suggesting potential involvement of pathways independent of LPL. Genetic mimicry of ANGPTL4 inhibition and LPL enhancement were associated with a lower risk of coronary heart disease and type 2 diabetes. These findings reinforce evidence that enhancing LPL activity (either directly or via upstream effects) through pharmacological approaches is likely to yield benefits to human health.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehaa972

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract
Graphical abstract CC BY-NC · PubMed Central
Figure 1 Associations of LPL (red), ANGPTL4 (blue), and ANGPTL3 (green) genotype with lipoprotein lipids and fatty acids. The associations were scaled so that each genotype is associated with 1-SD (∼0.55 mmol/L) lower concentration of triglycerides. The associations were meta-analysed across six population cohorts, up to 61 240 participants. P(diff) denotes the P-value for the comparison of the metabolic associations of ANGPTL3 (or ANGPTL4) with those of the LPL genotype. Closed symbols: P < 0.0002; open symbols: P ≥ 0.0002. C, cholesterol; DHA, Docosahexaenoic acid; FA, fatty acids; HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; TG, triglycerides; VLDL, very-low-density lipoprotein.
Figure 1 Associations of LPL (red), ANGPTL4 (blue), and ANGPTL3 (green) genotype with lipoprotein lipids and fatty acids. The associations were scaled so that each genotype is associated with 1-SD (∼0.55 mmol/L) lower concentration of triglycerides. The associations were meta-analysed across six population cohorts, up to 61 240 participants. P(diff) denotes the P-value for the comparison of the metabolic associations of ANGPTL3 (or ANGPTL4) with those of the LPL genotype. Closed symbols: P < 0.0002; open symbols: P ≥ 0.0002. C, cholesterol; DHA, Docosahexaenoic acid; FA, fatty acids; HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; TG, triglycerides; VLDL, very-low-density lipoprotein.CC BY-NC · PubMed Central
Figure 2 Associations of LPL (red), ANGPTL4 (blue), and ANGPTL3 (green) genotypes with the lipoprotein lipid compositions. Analyses details are as in Figure 1. TG% refers to the triglyceride concentration relative to total lipids within a single lipoprotein particle. Similar definition applied to C%. Closed symbols: P < 0.0002; open symbols: P ≥ 0.0002.
Figure 2 Associations of LPL (red), ANGPTL4 (blue), and ANGPTL3 (green) genotypes with the lipoprotein lipid compositions. Analyses details are as in Figure 1. TG% refers to the triglyceride concentration relative to total lipids within a single lipoprotein particle. Similar definition applied to C%. Closed symbols: P < 0.0002; open symbols: P ≥ 0.0002.CC BY-NC · PubMed Central
Figure 3 Associations of LPL (red), ANGPTL4 (blue), and ANGPTL3 (green) genotypes with non-lipid measures. Analyses details are as in Figure 1. Closed symbols: P < 0.0002; open symbols: P ≥ 0.0002.
Figure 3 Associations of LPL (red), ANGPTL4 (blue), and ANGPTL3 (green) genotypes with non-lipid measures. Analyses details are as in Figure 1. Closed symbols: P < 0.0002; open symbols: P ≥ 0.0002.CC BY-NC · PubMed Central
Figure 4 The effects of LPL, ANGTPL4, ANGPLT3 genotypes on GlycA (left) and CPR (right) compared with the effects of triglycerides on these markers. Associations of the variants and GRSs with GlycA were analysed in the present study, whilst associations with CRP were meta-analysed from CHARGE and UKBB. Details on the triglyceride and LDL cholesterol GRS are given in Supplementary material online, Figures S7 and S8. Closed symbols: P < 0.01 (corrected for multiple testing 0.05/5). Open symbols: P ≥ 0.01.
Figure 4 The effects of LPL, ANGTPL4, ANGPLT3 genotypes on GlycA (left) and CPR (right) compared with the effects of triglycerides on these markers. Associations of the variants and GRSs with GlycA were analysed in the present study, whilst associations with CRP were meta-analysed from CHARGE and UKBB. Details on the triglyceride and LDL cholesterol GRS are given in Supplementary material online, Figures S7 and S8. Closed symbols: P < 0.01 (corrected for multiple testing 0.05/5). Open symbols: P ≥ 0.01.CC BY-NC · PubMed Central
Figure 5 Associations of LPL (red), ANGPTL4 (blue), and ANGPTL3 (green) genotypes with (A) risk factors and (B) cardiometabolic endpoints. The detailed information on the source data (consortia or UK Biobank) used here is summarized in Supplementary material online, Table S3. For fasting insulin, as the instrument SNP was not available, proxy SNPs were used (rs3850634 for ANGPTL3 and rs11991231 for LPL, R 2 > 0.85 with the instrument SNP). However, no proxy with R 2 > 0.85 was found for ANGPTL4 rs116843064 and thus the result is missing from the figure. BMI, body mass index; WHRadjBMI, Waist-to-hip ratio adjusted for BMI. Closed symbols: P < 0.0002; open symbols: P ≥ 0.0002.
Figure 5 Associations of LPL (red), ANGPTL4 (blue), and ANGPTL3 (green) genotypes with (A) risk factors and (B) cardiometabolic endpoints. The detailed information on the source data (consortia or UK Biobank) used here is summarized in Supplementary material online, Table S3. For fasting insulin, as the instrument SNP was not available, proxy SNPs were used (rs3850634 for ANGPTL3 and rs11991231 for LPL, R 2 > 0.85 with the instrument SNP). However, no proxy with R 2 > 0.85 was found for ANGPTL4 rs116843064 and thus the result is missing from the figure. BMI, body mass index; WHRadjBMI, Waist-to-hip ratio adjusted for BMI. Closed symbols: P < 0.0002; open symbols: P ≥ 0.0002.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 91

Metadata

Authors
Wang, Q., Oliver-Williams, C., Raitakari, O. T., Viikari, J., Lehtimäki, T., Kähönen, M., Järvelin, M.-R., Salomaa, V., Perola, M., Danesh, J., Kettunen, J., Butterworth, A. S., Holmes, M. V., & Ala-Korpela, M.
Affiliations
  • Baker Heart and Diabetes Institute (AU)
  • MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge , Cambridge, UK
  • University of Turku (FI)
  • Tampere University (FI)
  • Oulu University Hospital (FI)
  • Finnish Institute for Health and Welfare (FI)
  • University of Helsinki (FI)
  • University of Cambridge (GB)
  • National Institute for Health and Care Research (GB)
  • Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu , Oulu, Finland
Corresponding author
Wang, Qin
Venue
European Heart Journal
Published
2020-12-22
Volume
42
Issue
12
Pages
1160-1169
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W3111241027
Cited by
89
References
22
Citations by year
2026: 5 · 2025: 18 · 2024: 22 · 2023: 29 · 2022: 7 · 2021: 7
FWCI
6.81
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • UTUPub (University of Turku) (submittedVersion)
  • Työväentutkimus Vuosikirja (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion, cc-by-nc)
  • Tampere University Institutional Repository (Tampere University) (submittedVersion, cc-by-nc)
  • STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
  • Apollo (University of Cambridge) (submittedVersion)
  • Apollo
Funders
  • The Academy of Finland (297338, 307247, 322098, 286284, 134309, 126925, 121584, 124282, 129378, 117787, 41071)
  • Novo Nordisk foundation (NNF17OC0027034, NNF17OC0026062)
  • Oulu Health and Wellfare Center
  • Social Insurance Institution of Finland
  • Competitive State Research Financing of the Expert Responsibility area of Kuopio
  • ERDF European Regional Development Fund (539/2010: A31592)
  • EU Horizon 2020 (633595, 755320)
  • EU Research Council (742927)
  • Sigrid Juselius
  • Finnish Cardiovascular Research
  • Juho Vainio
  • Paavo Nurmi
  • Finnish Cultural
  • Tampere Tuberculosis
  • Emil Aaltonen
  • Yrjö Jahnsson
  • Signe and Ane Gyllenberg
  • Finnish Diabetes Research
  • British Heart Foundation Intermediate Clinical Research Fellowship (FS/18/23/33512)
  • National Institute for Health Research Oxford Biomedical Research Centre
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
ANGPTL3, ANGPTL4, lipoprotein lipase, triglycerides, lipid profile, glycoprotein acetyls, C-reactive protein, waist-to-hip ratio, renal function, coronary artery disease, type 2 diabetes, cardiovascular risk
MeSH terms
Angiopoietin-like Proteins, Angiopoietin-Like Protein 4, Angiopoietin-Like Protein 3, Diabetes Mellitus, Type 2, Pharmaceutical Preparations, Humans, Angiopoietins, Mendelian Randomization Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis. https://app.cochat.ai/papers/10.1093/eurheartj/ehaa972
The paper
Wang, Q., Oliver-Williams, C., Raitakari, O. T., Viikari, J., Lehtimäki, T., Kähönen, M., Järvelin, M.-R., Salomaa, V., Perola, M., Danesh, J., Kettunen, J., Butterworth, A. S., Holmes, M. V., & Ala-Korpela, M. (2021). Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis. European Heart Journal. https://doi.org/10.1093/eurheartj/ehaa972

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.